New Landmarks to Slow the Progression of Chronic Kidney Disease
Conflicts of Interest
References
- Kovesdy, C.P. Epidemiology of chronic kidney disease: An update 2022. Kidney Int. Suppl. 2022, 12, 7–11. [Google Scholar] [CrossRef] [PubMed]
- Hill, N.R.; Fatoba, S.T.; Oke, J.L.; Hirst, J.A.; O’Callaghan, C.A.; Lasserson, D.S.; Hobbs, F.D.R. Global Prevalence of Chronic Kidney Disease—A Systematic Review and Meta-Analysis. PLoS ONE 2016, 11, e0158765. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ruiz-Ortega, M.; Rayego-Mateos, S.; Lamas, S.; Ortiz, A.; Rodrigues-Diez, R.R. Targeting the progression of chronic kidney disease. Nat. Rev. Nephrol. 2020, 16, 269–288. [Google Scholar] [CrossRef]
- Gansevoort, R.T.; Correa-Rotter, R.; Hemmelgarn, B.R.; Jafar, T.H.; Heerspink, H.J.L.; Mann, J.F.; Matsushita, K.; Wen, C.P. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 2013, 382, 339–352. [Google Scholar] [CrossRef] [PubMed]
- Spence, J.D.; Urquhart, B.L. Cerebrovascular Disease, Cardiovascular Disease, and Chronic Kidney Disease: Interplays and Influences. Curr. Neurol. Neurosci. 2022, 22, 757–766. [Google Scholar] [CrossRef] [PubMed]
- Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N. Engl. J. Med. 2004, 351, 1296–1305. [Google Scholar] [CrossRef]
- Castro-Alonso, C.; D’Marco, L.; Pomes, J.; Conill, M.D.A.; García-Diez, A.I.; Molina, P.; Puchades, M.J.; Valdivielso, J.M.; Escudero, V.; Bover, J.; et al. Prevalence of Vertebral Fractures and Their Prognostic Significance in the Survival in Patients with Chronic Kidney Disease Stages 3–5 Not on Dialysis. J. Clin. Med. 2020, 9, 1604. [Google Scholar] [CrossRef]
- Group KDIGO (KDIGO) C-MUW. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 2017, 7, 1–59. [Google Scholar] [CrossRef] [Green Version]
- Chapter 3: Management of progression and complications of CKD. Kidney Int. Suppl. 2013, 3, 73–90. [CrossRef] [Green Version]
- Oxford Medicine Online; Oxford University Press: Oxford, UK, 2015.
- Helal, I.; Fick-Brosnahan, G.M.; Reed-Gitomer, B.; Schrier, R.W. Glomerular hyperfiltration: Definitions, mechanisms and clinical implications. Nat. Rev. Nephrol. 2012, 8, 293–300. [Google Scholar] [CrossRef]
- Cortinovis, M.; Perico, N.; Ruggenenti, P.; Remuzzi, A.; Remuzzi, G. Glomerular hyperfiltration. Nat. Rev. Nephrol. 2022, 18, 435–451. [Google Scholar] [CrossRef] [PubMed]
- Chertow, G.; Luyckx, V.; Marsden, P.; Skorecki, K.; Taal, M. Brenner and Rector’s The Kidney, 11th ed.; Elsevier: Amsterdam, The Netherlands, 2019. [Google Scholar]
- Luyckx, V.A.; Tuttle, K.R.; Garcia-Garcia, G.; Gharbi, M.B.; Heerspink, H.J.L.; Johnson, D.W.; Liu, Z.-H.; Massy, Z.A.; Moe, O.; Nelson, R.G.; et al. Reducing major risk factors for chronic kidney disease. Kidney Int. Suppl. 2017, 7, 71–87. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chapter 1: Definition and classification of CKD. Kidney Int. Suppl. 2013, 3, 19–62. [CrossRef] [PubMed] [Green Version]
- Ferraro, P.M.; Agabiti, N.; Angelici, L.; Cascini, S.; Bargagli, A.M.; Davoli, M.; Gambaro, G.; Marino, C. Validation of a Classification Algorithm for Chronic Kidney Disease Based on Health Information Systems. J. Clin. Med. 2022, 11, 2711. [Google Scholar] [CrossRef] [PubMed]
- Niel, O.; Bastard, P. Artificial Intelligence in Nephrology: Core Concepts, Clinical Applications, and Perspectives. Am. J. Kidney Dis. 2019, 74, 803–810. [Google Scholar] [CrossRef] [PubMed]
- Radermacher, J.; Ellis, S.; Haller, H. Renal Resistance Index and Progression of Renal Disease. Hypertension 2002, 39, 699–703. [Google Scholar] [CrossRef] [Green Version]
- Romano, G.; Mioni, R.; Danieli, N.; Bertoni, M.; Croatto, E.; Merla, L.; Alcaro, L.; Pedduzza, A.; Metcalf, X.; Rigamonti, A.; et al. Elevated Intrarenal Resistive Index Predicted Faster Renal Function Decline and Long-Term Mortality in Non-Proteinuric Chronic Kidney Disease. J. Clin. Med. 2022, 11, 2995. [Google Scholar] [CrossRef]
- Sanz, A.B.; Ramos, A.M.; Soler, M.J.; Sanchez-Niño, M.D.; Fernandez-Fernandez, B.; Perez-Gomez, M.V.; Ortega, M.R.; Alvarez-Llamas, G.; Ortiz, A. Advances in understanding the role of angiotensin-regulated proteins in kidney diseases. Expert Rev. Proteomics. 2019, 16, 77–92. [Google Scholar] [CrossRef]
- Heerspink, H.J.L.; Parving, H.-H.; Andress, D.L.; Bakris, G.; Correa-Rotter, R.; Hou, F.-F.; Kitzman, D.W.; Kohan, D.; Makino, H.; McMurray, J.J.V.; et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. Lancet 2019, 393, 1937–1947. [Google Scholar] [CrossRef]
- Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2019, 380, 2295–2306. [Google Scholar] [CrossRef]
- Group, E.-K.C.; Herrington, W.G.; Staplin, N.; Wanner, C.; Green, J.B.; Hauske, S.J.; Emberson, J.R.; Preiss, D.; Judge, P.; Mayne, K.J.; et al. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2022. online ahead of print. [Google Scholar] [CrossRef]
- Lu, Y.-P.; Zhang, Z.-Y.; Wu, H.-W.; Fang, L.-J.; Hu, B.; Tang, C.; Zhang, Y.-Q.; Yin, L.; Tang, D.-E.; Zheng, Z.-H.; et al. SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease. J. Transl. Med. 2022, 20, 420. [Google Scholar] [CrossRef] [PubMed]
- Kohan, D.E.; Barton, M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014, 86, 896–904. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bakris, G.L.; Agarwal, R.; Anker, S.D.; Pitt, B.; Ruilope, L.M.; Rossing, P.; Kolkhof, P.; Nowack, C.; Schloemer, P.; Joseph, A.; et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2020, 383, 2219–2229. [Google Scholar] [CrossRef] [PubMed]
- Cupisti, A.; Gallieni, M.; Avesani, C.M.; D’Alessandro, C.; Carrero, J.J.; Piccoli, G.B. Medical Nutritional Therapy for Patients with Chronic Kidney Disease not on Dialysis: The Low Protein Diet as a Medication. J. Clin. Med. 2020, 9, 3644. [Google Scholar] [CrossRef] [PubMed]
- Castro-Barquero, S.; Arias-Guillén, M.; Pi-Oriol, S.; Sacanella, E.; Romano-Andrioni, B.; Vidal-Lletjós, S.; Ruiz-León, A.M.; Estruch, R.; Casas, R. A Comparative Study of the Efficacy of an Intervention with a Nutritional Supplement for Patients with Chronic Kidney Disease: A Randomized Trial. J. Clin. Med. 2022, 11, 1647. [Google Scholar] [CrossRef]
- Perez-Gomez, M.V.; Sanchez-Niño, M.D.; Sanz, A.B.; Martín-Cleary, C.; Ruiz-Ortega, M.; Egido, J.; Navarro-González, J.F.; Ortiz, A.; Fernandez-Fernandez, B. Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. J. Clin. Med. 2015, 4, 1325–1347. [Google Scholar] [CrossRef] [Green Version]
- Pitt, B.; Filippatos, G.; Agarwal, R.; Anker, S.D.; Bakris, G.L.; Rossing, P.; Joseph, A.; Kolkhof, P.; Nowack, C.; Schloemer, P.; et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N. Engl. J. Med. 2021, 385, 2252–2263. [Google Scholar] [CrossRef]
- Mazzaferro, S.; De Martini, N.; Cannata-Andía, J.; Cozzolino, M.; Messa, P.; Rotondi, S.; Tartaglione, L.; Pasquali, M.; Group OBOTE-EC-MW. Focus on the Possible Role of Dietary Sodium, Potassium, Phosphate, Magnesium, and Calcium on CKD Progression. J. Clin. Med. 2021, 10, 958. [Google Scholar] [CrossRef]
- Iorio, B.R.D.; Rocchetti, M.T.; De Angelis, M.; Cosola, C.; Marzocco, S.; Micco, L.D.; Di Bari, I.; Accetturo, M.; Vacca, M.; Gobbetti, M.; et al. Nutritional Therapy Modulates Intestinal Microbiota and Reduces Serum Levels of Total and Free Indoxyl Sulfate and P-Cresyl Sulfate in Chronic Kidney Disease (Medika Study). J. Clin. Med. 2019, 8, 1424. [Google Scholar] [CrossRef]
- Rocchetti, M.T.; Iorio, B.R.D.; Vacca, M.; Cosola, C.; Marzocco, S.; Di Bari, I.; Calabrese, F.M.; Ciarcia, R.; Angelis, M.D.; Gesualdo, L. Ketoanalogs’ Effects on Intestinal Microbiota Modulation and Uremic Toxins Serum Levels in Chronic Kidney Disease (Medika2 Study). J. Clin. Med. 2021, 10, 840. [Google Scholar] [CrossRef] [PubMed]
- Mirna, M.; Topf, A.; Wernly, B.; Rezar, R.; Paar, V.; Jung, C.; Salmhofer, H.; Kopp, K.; Hoppe, U.C.; Schulze, P.C.; et al. Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study. J. Clin. Med. 2020, 9, 886. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Foudi, N.; Palayer, M.; Briet, M.; Garnier, A.-S. Arterial Remodelling in Chronic Kidney Disease: Impact of Uraemic Toxins and New Pharmacological Approaches. J. Clin. Med. 2021, 10, 3803. [Google Scholar] [CrossRef] [PubMed]
- Carbonare, L.D.; Valenti, M.T.; Giannini, S.; Gallieni, M.; Stefani, F.; Ciresa, R.; Politi, C.; Fusaro, M. Bone Biopsy for Histomorphometry in Chronic Kidney Disease (CKD): State-of-the-Art and New Perspectives. J. Clin. Med. 2021, 10, 4617. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Simonini, M.; Vezzoli, G. New Landmarks to Slow the Progression of Chronic Kidney Disease. J. Clin. Med. 2023, 12, 2. https://doi.org/10.3390/jcm12010002
Simonini M, Vezzoli G. New Landmarks to Slow the Progression of Chronic Kidney Disease. Journal of Clinical Medicine. 2023; 12(1):2. https://doi.org/10.3390/jcm12010002
Chicago/Turabian StyleSimonini, Marco, and Giuseppe Vezzoli. 2023. "New Landmarks to Slow the Progression of Chronic Kidney Disease" Journal of Clinical Medicine 12, no. 1: 2. https://doi.org/10.3390/jcm12010002
APA StyleSimonini, M., & Vezzoli, G. (2023). New Landmarks to Slow the Progression of Chronic Kidney Disease. Journal of Clinical Medicine, 12(1), 2. https://doi.org/10.3390/jcm12010002